Shares in the penny stock of CytRx Corp. (Nasdaq: CYTR) may be on a turn around after closing at $0.323 in the last trading session. In the screen of upgrades and downgrades stocks, CYTR is now covered by Wall Street analysts Roth Capital who set a “buy” rating on the penny stock. CytRx, a biopharmaceutical research and development company specializing in oncology, has gained 15.36% ...
Continue Reading →APR